Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer

Autor: I. Vergote, E. Van Nieuwenhuysen, A. Casado, A. Laenen, D. Lorusso, E.I. Braicu, E. Guerra-Alia, P. Zola, P. Wimberger, P.R. Debruyne, E. Falcó, A. Ferrero, M.Z. Muallem, J. Kerger, E. García-Martinez, S. Pignata, J. Sehouli, T. Van Gorp, C. Gennigens, M.J. Rubio

Publikováno v: Gynecologic Oncology. 174:80-88

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1c869aa167ad5c4a8df05996dbc0f8c
https://doi.org/10.1016/j.ygyno.2023.04.028

LIO-1: Initiale Phase 2 Erfahrung mit Lucitanib + Nivolumab bei Patientinnen mit persistierendem oder rezidiviertem Zervixkarzinom (NCT04042116; ENGOT-GYN3/AGO/LIO)

Autor: F Heitz, A Oaknin, FJ Backes, E Van Nieuwenhuysen, RN Eskander, A González-Martín, V Makker, C Marth, M Patel, RT Penson, A Redondo, MJR Pérez, E Hamilton, P Wimberger, N Concin, J Go, K Wride, D Lepley, R Dusek, T Cameron, S Pignata

Publikováno v: 64. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V..

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e467c6b417f1afc6fe6efa11c32a396c
https://doi.org/10.1055/s-0042-1756856

Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort

Autor: E. Van Nieuwenhuysen, Ph Van Trappen, Annouschka Laenen, Ignace Vergote, K. Traen, F. Peeters, S. Ongaro, Frédéric Goffin, A. Kakkos, C. Ver Eecke, Evelyn Despierre

Publikováno v: European Journal of Surgical Oncology. 47:1117-1123

Objective To evaluate surgical and oncologic outcomes of patients treated by robot-assisted surgery for endometrial cancer within the Belgium Gynaecological Oncology Group (BGOG). Study design We performed a retrospective analysis of women with clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::493f6ba00563906888f5c7423fb9ffb4
https://doi.org/10.1016/j.ejso.2020.10.005

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

Autor: Y. Chai, S. Shacham, E Van Nieuwenhuysen, T.J. Unger, Anne L Kranich, T. Nottrup, Y. Landesman, Mansoor Raza Mirza, Morten Mau-Sørensen, Sileny Han, Charlotte Aaquist Haslund, Bente Lund, M. Kauffman, Ignace Vergote, J. Shah, A. Joshi, Marsha Crochiere, Nicole Concin, Tami Rashal, N. Au, Ulla Peen, Z. Umajuridze

Publikováno v: Vergote, I B, Lund, B, Peen, U, Umajuridze, Z, Mau-Sorensen, M, Kranich, A, Van Nieuwenhuysen, E, Haslund, C, Nottrup, T, Han, S N, Concin, N, Unger, T J, Chai, Y, Au, N, Rashal, T, Joshi, A, Crochiere, M, Landesman, Y, Shah, J, Shacham, S, Kauffman, M & Mirza, M R 2020, ' Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies ', Gynecologic Oncology, vol. 156, no. 2, pp. 308-314 . https://doi.org/10.1016/j.ygyno.2019.11.012

Background Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of selinexor in heavily pretreated, recurrent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9ff81ff5dfac1dd3abbd6fdb8002dcb
https://doi.org/10.1016/j.ygyno.2019.11.012